SomatostatinThird Party Manufacturing in India

Somatostatin works by binding to six G-protein-coupled somatostatin receptor subtypes, which are widely distributed throughout the body including the gastrointestinal tract, pancreas, pituitary gland, and central nervous system. Upon receptor activation, it inhibits adenylyl cyclase, reducing intracellular cyclic AMP levels and suppressing hormone secretion from target cells.

This broad inhibitory effect helps the body regulate excessive hormone secretion by reducing the release of growth hormone, thyroid-stimulating hormone, insulin, glucagon, gastrin, secretin, and vasoactive intestinal peptide. It also reduces gastric acid secretion, pancreatic enzyme secretion, and splanchnic blood flow, and slows gastrointestinal motility.

Unlike other peptide hormones that stimulate specific pathways, Somatostatin functions as a master inhibitory regulator, acting as a physiologic brake on endocrine and exocrine hypersecretion. Its anti-proliferative and anti-angiogenic properties further distinguish it, making it valuable for controlling neuroendocrine tumor growth and acute variceal bleeding.

Therapeutic Uses

Somatostatin is indicated for:

• Acute Variceal Bleeding: Control of acute bleeding from esophageal varices in patients with portal hypertension.
• Severe Gastrointestinal Bleeding: Management of bleeding from peptic ulcers, gastritis, and other GI sources.
• Neuroendocrine Tumors: Control of symptoms associated with carcinoid syndrome, VIPomas, glucagonomas, and insulinomas.
• Pancreatic Fistula: Reduction of pancreatic secretions to aid fistula closure.
• Acromegaly: Suppression of growth hormone hypersecretion (via synthetic analogs).

Why Manufacturers Choose Somatostatin

Somatostatin and its synthetic analogs are critical drugs in hospital settings, particularly in gastroenterology and emergency medicine. It is included in essential medicine lists for the management of acute variceal hemorrhage, a life-threatening complication of cirrhosis. The growing burden of liver disease and neuroendocrine tumors globally sustains consistent demand for this peptide.

This makes Somatostatin a high-value molecule for third party manufacturing in India, serving critical care, gastroenterology, and oncology departments in domestic and export markets.